Skip to main content

1 Result(s)

within John D. Markman Remove this filter

and

  1. Article

    Open Access

    Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial

    A recent phase 3, randomized, placebo- and tramadol-controlled trial (56-week treatment/24-week safety follow-up) demonstrated efficacy of tanezumab 10 mg in patients with chronic low back pain (CLBP) and a hi...

    John D. Markman, Thomas J. Schnitzer, Serge Perrot, Said R. Beydoun… in Pain and Therapy (2022)

    Download PDF (439 KB) View Article